15-min delayed · Sep 10, 3:15 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Revolution Medicines Inc, 19 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $72.00 to $320.00 (about 4.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $206.21 sits 2% above the current $202.89. The rating mix has stayed broadly stable, with Buy-side ratings easing from 19 to 18 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.07 next quarter toward $-5.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Strong Buy
Strong Buy15%
Buy1890%
Hold15%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Revolution Medicines Inc.
As of Sep, 18 of 19 firms rate RVMD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RVMD EPS & revenue forecast
EPS · NEXT QUARTER
$-2.07
Range $-3.68 – $-0.87 · 17 analysts · +11% YoY
Next period, 17 analysts expect Revolution Medicines Inc to earn $-2.07 a share (range $-3.68 – $-0.87), versus $-1.86 a year earlier. Full-year consensus is $-9.73, growing to $-5.85 the year after.
REVENUE · NEXT QUARTER
$143.6M
Range $0 – $356.3M · 17 analysts
Revenue is expected to reach $143.6M (range $0 – $356.3M). Full-year consensus is $171.8M, rising to $1.3B next year.
Top analysts covering Revolution Medicines Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RVMD.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$275.00+35.5% to target
Overall win rate
55%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #33
Buy
$251.00+23.7% to target
Overall win rate
48%
+ Follow
#3
Ami Fadia
Needham · Rank #67
Buy
$275.00+35.5% to target
Overall win rate
47%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$280.00+38.0% to target
Overall win rate
41%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #360
Buy
$260.00+28.1% to target
Overall win rate
33%
+ Follow
RVMD stock forecast FAQ
What is RVMD's average 12-month price target?+
The 18 analysts with a live target average $206.21 for Revolution Medicines Inc over the next 12 months, ranging from a $320.00 high to a $72.00 low.
Is RVMD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 20 analyst ratings, 19 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RVMD?+
The Street-high target is $320.00 (Evercore ISI Group), and the Street-low is $72.00. The average of all 18 active targets is $206.21.
How many Wall Street analysts cover RVMD?+
20 analysts have an active rating on Revolution Medicines Inc, and 18 firms carry a live 12-month price target.
Who is the most accurate analyst covering RVMD?+
Among analysts who currently cover RVMD, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $275.00 target.
What is Revolution Medicines Inc's projected EPS for next quarter?+
The consensus estimate is $-2.07 per share (range $-3.68 – $-0.87) across 17 analysts. Full-year EPS is projected at $-9.73, rising to $-5.85 the following year.
How much revenue is Revolution Medicines Inc expected to report next quarter?+
Consensus revenue is $143.6M (range $0 – $356.3M). Full-year revenue is projected at $171.8M, growing to $1.3B next year.
Have analysts been upgrading or downgrading RVMD lately?+
As of Sep, 18 of 19 firms rate RVMD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RVMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
